COVID-19. COVID-19 disease
Conditions
Interventions
Intervention 1: The intervention group in addition to standard treatment (400 mg of hydroxychloroquine and 100 to 400 mg of Lupinavir-ritonavir at a time), will receive 100 to 400 mg of Sofosbuvir-Ve
Sponsors
Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 18 years Absolute lymphocyte count <1100 / ML or SaO2 <93
Exclusion criteria
Exclusion criteria: Pregnancy or breast-feeding The physician's decision that the trial is not in the patient's interest Any circumstances that do not allow to follow the treatment protocol easily A history of severe liver disease including cirrhosis or ALT or AST levels more than fives times normal Drugs that are contraindicated with standard treatment or Sofosbuvir-Velpatasvir and cannot be discontinued History of untreated HIV infection or hepatitis C
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical status. Timepoint: Beginning of the study, 10 days later, or discharge time. Method of measurement: By a doctor. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Reza Khodarahmi
Kermanshah University of Medical Sciences
Outcome results
None listed